Conditions & Recovery · Oncology Brothers · June 15, 2026

ASCO 2026 GI Highlights: EMERALD-3, FIGHT-302, CIRCULATE, MATTERHORN

Welcome back to the Oncology Brothers podcast! In this episode we are joined by Dr. Neena Vijayvergia from Fox Chase Cancer Center to discuss the latest highlights from ASCO 2026, focusing on gastrointestinal (GI) studies. We discussed key studies: EMERALD-3 in HCC: Exploring the findings on combining TACE with Durvalumab and Tremelimumab, and the implications for patient outcomes. FIGHT-302 in Ch

Originally published by Oncology Brothers. We curate and add context; they did the reporting.

Read the full story at Oncology Brothers ↗

Related learning

Biotech Firm Claims Some Credit for Groundbreaking Virus Research Biotech Firm Claims Some Credit for Groundbreaking Virus Research James P. Allison, Ph.D., bangs gong after completing proton therapy treatment Combination therapy helps plasmacytoid bladder cancer survivor